GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AMAG Pharmaceuticals Inc (NAS:AMAG) » Definitions » Piotroski F-Score

AMAG Pharmaceuticals (AMAG Pharmaceuticals) Piotroski F-Score : 0 (As of Apr. 26, 2024)


View and export this data going back to 1986. Start your Free Trial

What is AMAG Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

AMAG Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for AMAG Pharmaceuticals's Piotroski F-Score or its related term are showing as below:


AMAG Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for AMAG Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AMAG Pharmaceuticals Piotroski F-Score Chart

AMAG Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 4.00 5.00 7.00 4.00

AMAG Pharmaceuticals Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 4.00 3.00 4.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep20) TTM:Last Year (Sep19) TTM:
Net Income was -200.152 + -24.491 + -13.244 + 9.702 = $-228.2 Mil.
Cash Flow from Operations was -19.965 + -46.609 + 3.167 + 36.679 = $-26.7 Mil.
Revenue was 89.484 + 68.661 + 52.755 + 93.106 = $304.0 Mil.
Gross Profit was 46.162 + 44.302 + 34.575 + 79.766 = $204.8 Mil.
Average Total Assets from the begining of this year (Sep19)
to the end of this year (Sep20) was
(966.608 + 791.227 + 753.575 + 715.549 + 734.356) / 5 = $792.263 Mil.
Total Assets at the begining of this year (Sep19) was $966.6 Mil.
Long-Term Debt & Capital Lease Obligation was $308.1 Mil.
Total Current Assets was $283.4 Mil.
Total Current Liabilities was $162.0 Mil.
Net Income was -25.013 + -122.084 + -121.169 + -23.94 = $-292.2 Mil.

Revenue was 86.167 + 75.804 + 77.767 + 83.808 = $323.5 Mil.
Gross Profit was 57.451 + 57.327 + 53.477 + 62.703 = $231.0 Mil.
Average Total Assets from the begining of last year (Sep18)
to the end of last year (Sep19) was
(1215.816 + 1175.459 + 1072.851 + 1024.2 + 966.608) / 5 = $1090.9868 Mil.
Total Assets at the begining of last year (Sep18) was $1,215.8 Mil.
Long-Term Debt & Capital Lease Obligation was $276.5 Mil.
Total Current Assets was $340.8 Mil.
Total Current Liabilities was $204.1 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

AMAG Pharmaceuticals's current Net Income (TTM) was -228.2. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

AMAG Pharmaceuticals's current Cash Flow from Operations (TTM) was -26.7. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep19)
=-228.185/966.608
=-0.23606778

ROA (Last Year)=Net Income/Total Assets (Sep18)
=-292.206/1215.816
=-0.24033735

AMAG Pharmaceuticals's return on assets of this year was -0.23606778. AMAG Pharmaceuticals's return on assets of last year was -0.24033735. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

AMAG Pharmaceuticals's current Net Income (TTM) was -228.2. AMAG Pharmaceuticals's current Cash Flow from Operations (TTM) was -26.7. ==> -26.7 > -228.2 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep19 to Sep20
=308.06/792.263
=0.38883553

Gearing (Last Year: Sep19)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep18 to Sep19
=276.468/1090.9868
=0.25341095

AMAG Pharmaceuticals's gearing of this year was 0.38883553. AMAG Pharmaceuticals's gearing of last year was 0.25341095. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep20)=Total Current Assets/Total Current Liabilities
=283.374/161.977
=1.7494706

Current Ratio (Last Year: Sep19)=Total Current Assets/Total Current Liabilities
=340.839/204.074
=1.67017356

AMAG Pharmaceuticals's current ratio of this year was 1.7494706. AMAG Pharmaceuticals's current ratio of last year was 1.67017356. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

AMAG Pharmaceuticals's number of shares in issue this year was 34.72. AMAG Pharmaceuticals's number of shares in issue last year was 33.906. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=204.805/304.006
=0.67368736

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=230.958/323.546
=0.71383358

AMAG Pharmaceuticals's gross margin of this year was 0.67368736. AMAG Pharmaceuticals's gross margin of last year was 0.71383358. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep19)
=304.006/966.608
=0.31450805

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep18)
=323.546/1215.816
=0.26611428

AMAG Pharmaceuticals's asset turnover of this year was 0.31450805. AMAG Pharmaceuticals's asset turnover of last year was 0.26611428. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+1+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

AMAG Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

AMAG Pharmaceuticals  (NAS:AMAG) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


AMAG Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of AMAG Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


AMAG Pharmaceuticals (AMAG Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1100 Winter Street, Waltham, MA, USA, 02451
AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.
Executives
Camber Capital Management Lp 10 percent owner 101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
Anthony Casciano officer: Chief Operating Officer C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Brian Piekos officer: Interim CFO C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
David Edward Johnson director, 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
James R Sulat director
Davey Scoon director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
John A. Fallon director C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
Anne M. Phillips director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Paul R. Fonteyne director C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Gino Santini director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Scott Dunseth Myers director, officer: President & CEO C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Schick officer: Chief Human Resources Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022

AMAG Pharmaceuticals (AMAG Pharmaceuticals) Headlines

From GuruFocus